Calcium Antagonists Market

Calcium antagonists are a group of medications that disrupt the movement of calcium (Ca2+) through calcium channels. Calcium channel blockers are used as antihypertensive drugs, i.e., as medications to decrease blood pressure in patients with hypertension. CCBs are particularly effective against large vessel stiffness, one of the common causes of elevated systolic blood pressure in elderly patients. Calcium channel blockers are also frequently used to alter heart rate (especially from atrial fibrillation), to prevent peripheral and cerebral vasospasm, and to reduce chest pain caused by angina pectoris.

N-type, L-type, and T-type voltage-dependent calcium channels are present in the zona glomerulosa of the human adrenal gland, and CCBs can directly influence the biosynthesis of aldosterone in adrenocortical cells, with consequent impact on the clinical treatment of hypertension with these agents.

CCBs have been shown to be slightly more effective than beta blockers at lowering cardiovascular mortality, but they are associated with more side effects. Potential major risks however were mainly found to be associated with short-acting CCBs.

Calcium Antagonists Market contains market size and forecasts of Calcium Antagonists in global, including the following market information:

Global Calcium Antagonists Market Revenue, 2017-2022, 2023-2028, ($ millions)

Global Calcium Antagonists Market Sales, 2017-2022, 2023-2028, (K Units)

Global top five Calcium Antagonists companies in 2021 (%)

The global Calcium Antagonists market was valued at million in 2021 and is projected to reach US$ million by 2028, at a CAGR of % during the forecast period.

The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.

Dihydropyridine Segment to Reach $ Million by 2028, with a % CAGR in next six years.

The global key manufacturers of Calcium Antagonists include Pfizer, Aventis, Searle, Bayer, AstraZeneca, Knoll Pharmaceuticals, Wyeth-Ayerst, Novartis and Sanofi, etc. In 2021, the global top five players have a share approximately % in terms of revenue.

We surveyed the Calcium Antagonists manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.

Total Market by Segment:

Global Calcium Antagonists Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Calcium Antagonists Market Segment Percentages, by Type, 2021 (%)

• Dihydropyridine
• Diltiazem
• Verapamil
• Others

Global Calcium Antagonists Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Calcium Antagonists Market Segment Percentages, by Application, 2021 (%)

• Hypertension
• Coronary Artery Disease
• Arrhythmia
• Ohers

Global Calcium Antagonists Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)

Global Calcium Antagonists Market Segment Percentages, By Region and Country, 2021 (%)

• North America
• US
• Canada
• Mexico
• Europe
• Germany
• France
• U.K.
• Italy
• Russia
• Nordic Countries
• Benelux
• Rest of Europe
• Asia
• China
• Japan
• South Korea
• Southeast Asia
• India
• Rest of Asia
• South America
• Brazil
• Argentina
• Rest of South America
• Middle East & Africa
• Turkey
• Israel
• Saudi Arabia
• UAE
• Rest of Middle East & Africa

Competitor Analysis

The report also provides analysis of leading market participants including:

• Key companies Calcium Antagonists revenues in global market, 2017-2022 (Estimated), ($ millions)
• Key companies Calcium Antagonists revenues share in global market, 2021 (%)
• Key companies Calcium Antagonists sales in global market, 2017-2022 (Estimated), (K Units)
• Key companies Calcium Antagonists sales share in global market, 2021 (%)

Further, the report presents profiles of competitors in the market, key players include:

• Pfizer
• Aventis
• Searle
• Bayer
• AstraZeneca
• Knoll Pharmaceuticals
• Wyeth-Ayerst
• Novartis
• Sanofi
• Baiyunshan Pharmaceutical
• South China Pharmaceutical Group
• Tianjin Tanabe Seiyaku